Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines

Clinical and Experimental Metastasis

Volumn 18, Issue 2, 2000, Pages 163-170

  Angelucci, A ^a   D'Ascenzo, S ^a   Festuccia, C ^a   Gravina, G L ^a   Bologna, M ^a   Dolo, V ^a   Pavan, A ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Membrane vesicles; Prostate cancer; Tumor invasion; Urokinase plasminogen activator

Indexed keywords

COLLAGEN; PROTEINASE; UROKINASE;

ARTICLE; CANCER INVASION; CELL TRANSFORMATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; MEMBRANE VESICLE; PROSTATE CANCER; WESTERN BLOTTING; ZYMOGRAPHY;

3T3 CELLS; ANIMALS; BLOTTING, WESTERN; COLLAGEN; CULTURE MEDIA, CONDITIONED; DRUG COMBINATIONS; HUMANS; HYDROLYSIS; LAMININ; MALE; MICE; MICROSCOPY, IMMUNOELECTRON; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEOGLYCANS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0035118749     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006778000173     Document Type: Article

References (30)

1. Activation of plasminogen: A general mechanism for producing localized extracellular proteolysis
2. Biology and biochemistry of proteinases in tumor invasion
3. Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface
4. Plasminogen activator inhibitor type I stabilized vitronectin-dependent adhesion in HT1080 cells
5. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy
6. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
7. Prourokinase activation on the surface of human rhabdomyosarcoma cells: Localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor
8. Plasminogen activators tissue degradation and cancer
9. Studies on the ability of 65 kDa and 92 kDa tumor cell gelatinases to degrade type IV collagen
10. Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines
11. Effect of phorbol ester and cytokines on matrix metalloproteinases and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines
12. Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells
13. Shedding of plasma membrane fragments. Neoplastic and developmental importance
14. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro
15. Comparative lipid analysis of purified plasma membranes and shed extracellular membrane vesicles from normal routine thymocytes and leukemia GSRL cells
16. Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities
17. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells
18. Selective localization of matrix metalloproteinase 9, βl integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells
19. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
20. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials
21. A rapid in vitro assay for quantitating the invasive potential of tumor cells
22. Membrane vesicles shed into extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens
23. Arrest and metastasis of blood-borne tumor cells are modified by fusion of plasma membrane vesicles from highly metastatic cells
24. Membrane vesicles in ovarian cancer fluids: A new potential marker
25. Plasminogen activation initiated by single chain urokinase type plasminogen activator. Potentiation by U937 monocytes
26. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma
27. Mechanisms for pro-matrix metalloproteinase activation
28. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration
29. Laminin and other basement membrane components
30. A synthetic pentapeptide from the B1 chain of laminin is chemotactic for B16F10 melanoma cells